Field & Main Bank’s Moderna MRNA Stock Holding History

Field & Main Bank’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7K	Hold	100	–	–	﹤0.01%	244
2026 Q1	$5.08K	Hold	100	–	–	﹤0.01%	242
2025 Q4	$2.95K	Hold	100	–	–	﹤0.01%	249
2025 Q3	$2.58K	Hold	100	–	–	﹤0.01%	244
2025 Q2	$2.76K	Hold	100	–	–	﹤0.01%	231
2025 Q1	$2.83K	Hold	100	–	–	﹤0.01%	232
2024 Q4	$4.16K	Hold	100	–	–	﹤0.01%	244
2024 Q3	$6.68K	Hold	100	–	–	﹤0.01%	226
2024 Q2	$11.9K	Hold	100	–	–	﹤0.01%	219
2024 Q1	$10.7K	Hold	100	–	–	﹤0.01%	222
2023 Q4	$9.95K	Hold	100	–	–	﹤0.01%	220
2023 Q3	$10.3K	Hold	100	–	–	﹤0.01%	221
2023 Q2	$12.2K	Hold	100	–	–	0.01%	222
2023 Q1	$15.4K	Hold	100	–	–	0.01%	209
2022 Q4	$18K	Hold	100	–	–	0.01%	207
2022 Q3	$12K	Hold	100	–	–	0.01%	227
2022 Q2	$14K	Hold	100	–	–	0.01%	236
2022 Q1	$17K	Hold	100	–	–	0.01%	195
2021 Q4	$25K	Buy	+100	New	+$29.2K	0.01%	186

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Field & Main Bank's MRNA Position: Q2 2026 in Review

Field & Main Bank held its Moderna (MRNA) position steady in Q2 2026 at 100 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #244.

Field & Main Bank first reported a position in MRNA in Q4 2021 and has held it in 19 quarters since. The position peaked at $25K in Q4 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Field & Main Bank held 100 shares of Moderna worth $7K as of Q2 2026.
Field & Main Bank left its Moderna share count unchanged in Q2 2026.
Moderna made up ﹤0.01% of Field & Main Bank's portfolio in Q2 2026, its #244 holding.
Field & Main Bank first reported a position in Moderna in Q4 2021 and has held it in 19 quarters since.
Field & Main Bank's Moderna position peaked at $25K in Q4 2021.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Field & Main Bank's 13F filing for Q2 2026, filed 13 Aug 2026.